These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 19320488)

  • 1. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
    J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
    J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.
    Pettersson H; Bülow A; Ek F; Jensen J; Ottesen LK; Fejzic A; Ma JN; Del Tredici AL; Currier EA; Gardell LR; Tabatabaei A; Craig D; McFarland K; Ott TR; Piu F; Burstein ES; Olsson R
    J Med Chem; 2009 Apr; 52(7):1975-82. PubMed ID: 19338356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
    Du W; Jewell JP; Lin LS; Colandrea VJ; Xiao JC; Lao J; Shen CP; Bateman TJ; Reddy VB; Ha SN; Shah SK; Fong TM; Hale JJ; Hagmann WK
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5195-9. PubMed ID: 19632830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.
    Armstrong HE; Galka A; Lin LS; Lanza TJ; Jewell JP; Shah SK; Guthikonda R; Truong Q; Chang LL; Quaker G; Colandrea VJ; Tong X; Wang J; Xu S; Fong TM; Shen CP; Lao J; Chen J; Shearman LP; Stribling DS; Rosko K; Strack A; Ha S; Van der Ploeg L; Goulet MT; Hagmann WK
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2184-7. PubMed ID: 17293109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
    Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
    J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
    Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists.
    Pasternak A; Goble SD; deJesus RK; Hreniuk DL; Chung CC; Tota MR; Mazur P; Feighner SD; Howard AD; Mills SG; Yang L
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6237-40. PubMed ID: 19767208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
    Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
    Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
    Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
    J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas.
    McBriar MD; Guzik H; Shapiro S; Paruchova J; Xu R; Palani A; Clader JW; Cox K; Greenlee WJ; Hawes BE; Kowalski TJ; O'neill K; Spar BD; Weig B; Weston DJ; Farley C; Cook J
    J Med Chem; 2006 Apr; 49(7):2294-310. PubMed ID: 16570926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
    Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
    J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted pyrimidines as cannabinoid CB1 receptor ligands.
    Kim MJ; Kim JY; Seo HJ; Lee J; Lee SH; Kim MS; Kang J; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4692-7. PubMed ID: 19596576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.